Lexicon Pharmaceuticals
LXRX
99 hedge funds and large institutions have $749M invested in Lexicon Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 35 reducing their positions, and 12 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less funds holding
Funds holding: 103 → 99 (-4)
8% less capital invested
Capital invested by funds: $813M → $749M (-$63.6M)
26% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 35
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
Top Buyers
| 1 |
Norges Bank
Oslo,
Norway
|
+$3.89M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.01M |
| 3 |
UBS AM
Chicago,
Illinois
|
+$750K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$265K |
| 5 |
Morgan Stanley
New York
|
+$219K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
D.E. Shaw & Co
New York
| – | -$66K | -5,472 | Closed |
|
|
CAM
102
Capstone Asset Management
Houston,
Texas
| – | -$37K | -3,072 | Closed |
|
|
NCCM
103
Nine Chapters Capital Management
Short Hills,
New Jersey
| – | -$34K | -2,843 | Closed |
|
|
SB
104
Suntrust Banks
Atlanta,
Georgia
| – | -$33K | -2,794 | Closed |
|
|
BBA
105
BLB&B Advisors
Montgomeryville,
Pennsylvania
| – | -$31K | -2,536 | Closed |
|
|
VF
106
Virtu Financial
New York
| – | -$29K | -2,398 | Closed |
|
|
PPA
107
Parametric Portfolio Associates
Seattle,
Washington
| – | -$25K | -2,066 | Closed |
|
|
VKH
108
Virtu KCG Holdings
New York
| – | -$18K | -1,503 | Closed |
|
109
BNP Paribas Financial Markets
Paris,
France
| – | -$1.61K | -150 | Closed |
|
|
FWM
110
Focused Wealth Management
Newburgh,
New York
| – | +$75 | +7 | New |
|
LXRX Hedge Fund Activity: Q2 2014 in Review
99 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q2 2014, worth a combined $749M — down 7.8% from $813M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of LXRX and 8 opened new positions — a net loss of 4 holders — while 35 trimmed existing stakes and 26 added.
The largest buyer was Norges Bank, adding an estimated $3.89M. The largest seller was State Street, cutting an estimated $6.17M.
- 99 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q2 2014, down from 103 in Q1 2014.
- Funds reported $749M of Lexicon Pharmaceuticals stock for Q2 2014, down 7.8% quarter-over-quarter.
- 8 funds opened new Lexicon Pharmaceuticals positions in Q2 2014 and 12 closed out, a net change of -4 holders.
- The largest Lexicon Pharmaceuticals buyer in Q2 2014 was Norges Bank, an estimated $3.89M added.
- The largest Lexicon Pharmaceuticals seller in Q2 2014 was State Street, an estimated $6.17M sold.
Based on aggregated 13F filings for Q2 2014.